Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. ACN

Go back to Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
(NASDAQ: MDCX) Delayed: 0.17 --0 (-0%)
Previous Close $0.17    52 Week High $ 
Open $0.17    52 Week Low $ 
Day High $0.20    P/E N/A 
Day Low $0.16    EPS $ 
Volume 23,055,767       

(NASDAQ: MDCX) Delayed: 0.17 --0 (-0%)
Previous Close $0.17    52 Week High $ 
Open $0.17    52 Week Low $ 
Day High $0.20    P/E N/A 
Day Low $0.16    EPS $ 
Volume 23,055,767